Lv4
440 积分 2023-10-02 加入
Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia following Venetoclax plus Hypomethylating Agent Therapy
5小时前
已完结
维奈克拉联合治疗急性髓系白血病的疗效和预后因素分析
1个月前
已完结
Venetoclax and beyond: New Horizons in CLL and AML therapy
1个月前
已完结
Azacytidine and Venetoclax as a Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia: A Single Centre Experience
1个月前
已完结
Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia following Venetoclax plus Hypomethylating Agent Therapy
2个月前
已完结
The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN–GIL hybrid single-molecule inhibitors
2个月前
已完结
Flavokawain a induces cell cycle arrest through CDT1-dependent p27 regulation and synergizes with venetoclax in acute myeloid leukemia
2个月前
已完结
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multi-center Cohort Study
3个月前
已完结
Salinomycin sodium exerts anti diffuse large B-cell lymphoma activity through inhibition of LRP6-mediated Wnt/β-catenin and mTORC1 signaling
4个月前
已完结
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
4个月前
已完结
皖公网安备34019202002308
